1. Home
  2. PRAX vs FUL Comparison

PRAX vs FUL Comparison

Compare PRAX & FUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PRAX
  • FUL
  • Stock Information
  • Founded
  • PRAX 2015
  • FUL 1887
  • Country
  • PRAX United States
  • FUL United States
  • Employees
  • PRAX N/A
  • FUL N/A
  • Industry
  • PRAX Biotechnology: Pharmaceutical Preparations
  • FUL Home Furnishings
  • Sector
  • PRAX Health Care
  • FUL Industrials
  • Exchange
  • PRAX Nasdaq
  • FUL Nasdaq
  • Market Cap
  • PRAX 4.0B
  • FUL 3.2B
  • IPO Year
  • PRAX 2020
  • FUL N/A
  • Fundamental
  • Price
  • PRAX $179.18
  • FUL $58.39
  • Analyst Decision
  • PRAX Strong Buy
  • FUL Strong Buy
  • Analyst Count
  • PRAX 12
  • FUL 5
  • Target Price
  • PRAX $212.42
  • FUL $70.20
  • AVG Volume (30 Days)
  • PRAX 978.5K
  • FUL 399.2K
  • Earning Date
  • PRAX 11-05-2025
  • FUL 09-24-2025
  • Dividend Yield
  • PRAX N/A
  • FUL 1.60%
  • EPS Growth
  • PRAX N/A
  • FUL N/A
  • EPS
  • PRAX N/A
  • FUL 2.07
  • Revenue
  • PRAX $7,463,000.00
  • FUL $3,502,085,000.00
  • Revenue This Year
  • PRAX N/A
  • FUL N/A
  • Revenue Next Year
  • PRAX $44.43
  • FUL $2.36
  • P/E Ratio
  • PRAX N/A
  • FUL $28.39
  • Revenue Growth
  • PRAX 364.98
  • FUL N/A
  • 52 Week Low
  • PRAX $26.70
  • FUL $47.56
  • 52 Week High
  • PRAX $206.71
  • FUL $78.68
  • Technical
  • Relative Strength Index (RSI)
  • PRAX 62.04
  • FUL 48.28
  • Support Level
  • PRAX $159.74
  • FUL $56.96
  • Resistance Level
  • PRAX $188.53
  • FUL $58.91
  • Average True Range (ATR)
  • PRAX 13.41
  • FUL 1.27
  • MACD
  • PRAX -5.00
  • FUL -0.00
  • Stochastic Oscillator
  • PRAX 47.30
  • FUL 35.08

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

Share on Social Networks: